Healthcare
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.
About this update from Abbvie Inc.
IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience. "Stemming from its origins in wound-healing research, SkinMedica was founded on the principles of regenerative skincare," said Glen Curran, senior vice president, Allergan Aesthetics. "For more than 25 years, the brand has consistently advanced science-backed solutions, and today we're excited to introduce initiatives that continue to reinforce its mission to support skin health from cell to surface." SkinMedica's Regenerative Science Advisory Board SkinMedica has launched the Regenerative Science Advisory Board , a collective of leading physicians, clinicians, and skin health experts from across the country. Through in-person collaboration, virtual consultations, and curated content across SkinMedica-owned platforms, the advisory board will foster scientific dialogue, share clinical best practices, and help bridge breakthrough research with everyday patient care. "Scientific innovation is most impactful when it is informed by the clinicians and experts who bring it to life every day," said Curran. "We're honored to welcome this distinguished group of thought leaders to the SkinMedica Regenerative Science Advisory Board. Their expertise and real-world perspective will help advance scientific education, strengthen collaboration across the aesthetic community, inform future conversations around skin longevity and innovation; while ensuring we continue to translate breakthrough science into meaningful solutions for providers and patients." State-of-the-Art R&D Facility The advisory board reinforces Allergan Aesthetics' leadership in professional-grade skincare and complements its continued investment in SkinMedica innovation, including the recent expansion of the SkinMedica R&D lab in Irvine, Calif. The state-of-the-art lab supports a broad range of pre-clinical research and sophisticated imaging technologies that provide deeper insight into skin biology. SkinMedica is also leveraging artificial intelligence and machine learning to identify novel biological targets, accelerate ingredient discovery, and advance understanding of the cellular drivers of skin longevity to solve for unmet skin concerns.